SEARCH:   Advanced

Blood, 1 February 2008, Vol. 111, No. 3, pp. 1124-1127. Prepublished online as a Blood First Edition Paper on November 13, 2007; DOI 10.1182/blood-2007-06-093302. This Article Full Text Full Text (PDF) Supplemental Tables and Figures All Versions of this Article: blood-2007-06-093302v1 111/3/1124    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Archambeault, S. Articles by Loh, M. L. Search for Related Content PubMed PubMed Citation Articles by Archambeault, S. Articles by Loh, M. L. Related Collections Brief Reports Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Brief Report Development of an allele-specific minimal residual disease assay for patients with juvenile myelomonocytic leukemia Sophie Archambeault1, Nikki J. Flores1, Ayami Yoshimi2, Christian P. Kratz2, Miriam Reising2, Alexandra Fischer2, Peter Noellke2, Franco Locatelli2, Petr Sedlacek2, Christian Flotho2, Marco Zecca2, Peter D. Emanuel3, Robert P. Castleberry3, Charlotte M. Niemeyer2, Peter Bader2, and Mignon L. Loh1,3,4 1 Department of Pediatrics, University of California, San Francisco; 2 European Working Group of Myelodysplastic Syndromes in Childhood; 3 Children's Oncology Group, Arcadia, CA; and 4 Comprehensive Cancer Center, University of California, San Francisco Juvenile myelomonocytic leukemia is an aggressive and frequently lethal myeloproliferative disorder of childhood. Somatic mutations in NRAS, KRAS, or PTPN11 occur in 60% of cases. Monitoring disease status is difficult because of the lack of characteristic leukemic blasts at diagnosis. We designed a fluorescently based, allele-specific polymerase chain reaction assay called TaqMAMA to detect the most common RAS or PTPN11 mutations. We analyzed peripheral blood and/or bone marrow of 25 patients for levels of mutant alleles over time. Analysis of pre–hematopoietic stem-cell transplantation, samples revealed a broad distribution of the quantity of the mutant alleles. After hematopoietic stem-cell transplantation, the level of the mutant allele rose rapidly in patients who relapsed and correlated well with falling donor chimerism. Simultaneously analyzed peripheral blood and bone marrow samples demonstrate that blood can be monitored for residual disease. Importantly, these assays provide a sensitive strategy to evaluate molecular responses to new therapeutic strategies. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: K. Foucar Myelodysplastic/Myeloproliferative Neoplasms Am J Clin Pathol, August 1, 2009; 132(2): 281 - 289. [Abstract] [Full Text] [PDF]

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020